Category Archives: Business and Investments

Latest From Business and Investments

Know Your IP Strategy: A Necessity for Technology Start-ups

Annemarie_Meike

The Licensing Executives Society Foundation invites start-up companies, with investments of less than $200,000, and graduate students from around the world to participate in their annual International Business Plan Competition. The Competition requires participants to submit a business plan with an intellectual property component and strategies explaining how intellectual property will be used to achieve business objectives. Before the first round submission deadline, the Competition pairs registered teams with senior leaders in the intellectual property Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post

Interstitial Cystitis: Understanding What It Is, and the Interstitial Cystitis Association’s Role in an IC Patient’s Life

scientist, lab

If you mention Interstitial Cystitis (IC) to most people, including physicians, the majority of people have no idea what you are talking about. This is alarming because IC affects between 4-12 million people, just in the U.S. alone.  The majority of IC patients are women, but both men and children can receive the diagnosis as well.  So what is IC and how do you know if you have it? Interstitial cystitis (in-ter-stish-uhl sĭ-stī’tĭs), or as Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

The Liquid Gold Rush For Biopsies

Liquid biopsy is considered “liquid gold”. Estimates the global testing market to reach $20 billion by 2020.

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Setting the Record Straight on Innovation and Drug Development

stethoscope

Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, researchers and investors working in this field have firmly established themselves at the forefront of medical innovation and the search for new cures and therapies for previously untreatable diseases. That’s why it is important that policy proposals designed to respond to the activities of outliers like Turing Pharmaceuticals and Valeant do not hurt America’s leadership in biotechnology innovation and investment. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Do Outcomes Matter When There Is Chronic Misalignment?

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. With over $3 trillion in annual healthcare spending, a relatively young population, and shorter life expectancies than other western nations, one would think there would be vast opportunities for the U.S. healthcare industry to rein in costs, weed out inefficiency, and improve outcomes. Instead of yielding to “regression toward the mean,” however, the highest global per capita healthcare machine marches to 20 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,